Earnings History Data for Unicycive Therapeutics, Inc. (UNCY) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Unicycive Therapeutics, Inc.
Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28-03-2024 | AH | UNCY | Unicycive Therapeutics | 50.00 | -0.16 | -0.18 | 0.00 | Unicycive Therapeutics GAAP EPS of -$1.28, revenue of $0.7M [3/28/2024 5:03 PM] |
1.38 | -0.08 (-5.48%) |
1.38 | 0.0 (0.00%) |
0.47 - 2.29 | 167,704 | 400,000 | 4,075 | ||
| 14-08-2023 | AH | UNCY | Unicycive Therapeutics | 14.00 | -0.29 | -0.39 | 0.00 | Unicycive Therapeutics GAAP EPS of $0.29 beats by $0.57 [8/15/2023 10:30 AM] |
0.7966 | -0.02 (-2.91%) |
0.86 | 0.04 (4.81%) |
0.40 - 2.87 | 110,786 | 80,000 | 1,722 | ||
| 16-05-2023 | PM | UNCY | Unicycive Therapeutics | 21.00 | -0.29 | -0.36 | 0.00 | Unicycive Therapeutics GAAP EPS of -$0.24 [5/16/2023 9:20 AM] |
1.38 | -0.05 (-3.50%) |
0.0 | 0.0 (0.00%) |
0.40 - 2.87 | 63,207 | 350,000 | 0 | ||
| 31-03-2023 | PM | UNCY | Unicycive Therapeutics, Inc. | 7.77 | -0.35 | -0.38 | -0.17 | Unicycive Therapeutics GAAP EPS of -$1.20 misses by $0.11 [3/31/2023 7:50 AM] |
2.07 | 0.19 (10.11%) |
1.88 | 0.0 (0.00%) |
0.40 - 2.87 | 932,788 | 940,000 | 2,577 | ||
| 14-11-2022 | PM | UNCY | Unicycive Therapeutics | 10.00 | -0.37 | -0.35 | 0.00 | Unicycive Therapeutics GAAP EPS of -$0.37 misses by $0.09, revenue of $0.95M [11/14/2022 9:12 AM] |
0.6750 | -0.04 (-5.59%) |
0.70 | -0.01 (-2.10%) |
0.51 - 3.10 | 21,197 | 30,000 | 600 | ||
| 15-08-2022 | PM | UNCY | Unicycive Therapeutics, Inc. | 12.02 | -0.24 | -0.27 | -0.13 | Unicycive Therapeutics GAAP EPS of -$0.24 [8/16/2022 3:12 AM] |
0.70 | 0.0 (-0.03%) |
0.0 | 0.0 (0.00%) |
0.62 - 3.19 | 22,810 | 100,000 | 0 | ||
| 12-05-2022 | PM | UNCY | Unicycive Therapeutics | 11.00 | -0.24 | -0.20 | 0.00 | Unicycive Therapeutics GAAP EPS of -$0.24 misses by $0.07 [5/12/2022 8:21 AM] |
0.70 | -0.02 (-2.79%) |
0.0 | 0.0 (0.00%) |
0.62 - 8.73 | 70,750 | 40,000 | 0 | ||
| 11-11-2021 | PM | UNCY | Unicycive Therapeutics | 41.00 | -0.37 | -0.11 | 0.00 | Unicycive Therapeutics reports Q3 results [11/11/2021 9:29 AM] |
2.79 | 0.04 (1.45%) |
0.0 | 0.0 (0.00%) |
2.39 - 8.73 | 47,239 | 130,000 | 0 | ||